NEW YORK, NY--(Marketwire - March 01, 2010) -
China Aoxing Pharmaceutical Company, Inc.
) ("China Aoxing"), a China-based pharmaceutical company
specializing in research, development, manufacturing and distribution of
narcotic and pain-management products, today announced the Company's
participation in the following conferences.
-- Rodman & Renshaw Annual China Investment Conference, to be held
March 7-9, 2010 at the Regent Hotel, Beijing, China. Management present
at 11:05 am Beijing Time on March 8 and meet with institutional
investors throughout March 8 and 9;
-- Roth 22nd Annual OC Growth Stock Conference, to be held March 14-17,
2010 at The Ritz-Carlton, Laguna Niguel, California. Management present
at 8:00 am Pacific Time on March 17 and meet institutional investors
throughout March 16 and 17.
For further details, please contact your institutional sales representative.
About China Aoxing Pharmaceutical Company, Inc.
China Aoxing Pharmaceutical Company, Inc. (OTCBB: CAXG) is a pharmaceutical
company located in China specializing in research, development,
manufacturing and distribution of a variety of narcotics and
pain-management products. It has international strategic alliances with
QRxPharma Limited and American Oriental Bioengineering, Inc. (NYSE: AOB) in
commercializing narcotic and pain management products for China and
ex-China markets. Headquartered in Shijiazhuang City, the pharmaceutical
capital of China, outside of Beijing, China Aoxing has China's largest and
the most advanced manufacturing facility for highly regulated narcotic
medicines, addressing a very under-served and fast-growing market in China.
Its facility is one of the few GMP facilities licensed for narcotics
medicines. The Company is working closely with the Chinese government and
SFDA to assure the strictly regulated availability to medical professionals
of its narcotic drugs and pain medicines throughout China. For more
Statements made in this press release are forward-looking and are made
pursuant to the safe harbor provisions of the Securities Litigation Reform
Act of 1995. Such statements involve risks and uncertainties that may
cause actual results to differ materially from those set forth in these
statements. The economic, competitive, governmental, technological and
other risk factors identified in the Company's filings with the Securities
and Exchange Commission, including the Form 10-K for the year ended June
30, 2009, may cause actual results or events to differ materially from
those described in the forward looking statements in this press release.
The Company undertakes no obligation to publicly update or revise any
forward-looking statements, whether because of new information, future
events, or otherwise.